Your Messages Inbox
Your Article Summary
See Latest ArticlesUpdate on FDA Registration of Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
Chugai Pharmaceutical Co., 01/23/09
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereafter, "Chugai")] and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan (hereafter "Roche")] announced today that the U.S. Food and Drug Administration (FDA) has provided further guidance on requirements for the Biologics License Application (BLA) for Actemra, the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody as a treatment for moderately to severely active rheumatoid arthritis (RA).
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor